2024 October 3rd release (#31)

docs/content-changelog.md

@@ -1,6 +1,19 @@
 # Content Changelog
 The following changes have been made to the content catalogued within the Molecular Oncology Almanac knowledge base.
 
+## October 2024 release
+Added entries:
+- (FDA) [_EGFR_ p.L858R and exon 19 deletions and sensitivty to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of patients with non-small cell lung cancer](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19).
+- (FDA) [_EGFR_ p.L858R and exon 19 deletions and sensitivty to osimertinib for the treatment of patients with non-small cell lung cancer](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer).
+
+Revised entries:
+- (FDA) [_RET_ somatic variants and sensitivity to selpercatinib for the treatment of patients with medullary thyroid cancer received an approval from the FDA, previously accelerated approval.](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-medullary-thyroid-cancer-ret-mutation)
+- (FDA) The `description` of three records corresponding to FDA approved indications for osimertinib were edited for clarity. 
+- (FDA) Six records for capivasertib in combination with fulvestrant incorrectly categorized fulvestrant as a targeted therapy. It has been updated to be a hormone therapy, and the `therapy_type` for each of these records has been updated to be "Combination therapy".
+- (Clinical evidence) The PMID for Bostner et al. was incorrected listed as "7486065" instead of "17486065". The evidence category was also changed from Clinical evidence to Clinical trial. Thank you, [Cameron Grisdale](https://github.com/vanallenlab/moalmanac-browser/issues/45)! 
+
+Four records listed therapy type either as "Targeted therapy + Chemotherapy", "Targeted therapy + Chemotherapy + Chemotherapy", or "Chemotherapy + Targeted therapy + Chemotherapy" instead of "Combination therapy". These records have been updated.
+
 ## September 2024 release
 Added entries:
 - (FDA) _IDH1_ and _IDH2_ somatic variants and sensitivity to vorasidenib for patients with astrocytoma and oligodendroglioma. Specifically, _IDH1_ p.R132C, p.R132G, p.R132H, p.R132L, p.R132S, and _IDH2_ p.R172K and p.172G.